Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo

Original Article

DOI: 10.1007/s00280-006-0282-x

Cite this article as:
Lin, J., Yan, XJ. & Chen, HM. Cancer Chemother Pharmacol (2007) 59: 439. doi:10.1007/s00280-006-0282-x



This study was to evaluate the correlation of two important strategies, namely, cell cycle proliferation arrest and anti-angiogenesis. We chose fascaplysin, a marine natural product with selective CDK4 selective inhibition activity, to study its potential anti-angiogenesis effects in vivo and in vitro.


Chorioallantoic membrane (CAM) assay was initially used as an in vivo approach to evaluate anti-angiogenic activity of fascaplysin. In addition, human umbilical vein endothelial cell (HUVEC) line was used to further confirm the anti-angiogenic activity of fascaplysin in vitro. To explore the mechanism of anti-angiogenesis, we examined the effect of fascaplysin on vascular endothelial growth factor (VEGF) expression and secretion by hepatocarcinoma cells BeL-7402.


The results of CAM assay suggested fascaplysin inhibited capillary plexus formation in a dose-dependent manner and suppressed VEGF in cross section. Moreover, the in vitro assay also confirmed that fascaplysin provided selective inhibition of endothelial cells proliferation towards tumor cells in low concentration. The immunocytochemical staining and ELISA verified fascaplysin could inhibit VEGF expression and secretion by BeL-7402.


These findings strongly suggest that fascaplysin is a natural angiogenesis inhibitor.


Fascaplysin Anti-angiogenesis CAM HUVEC VEGF 

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Marine Biotechnology LaboratoryNingbo UniversityNingbo People’s Republic of China